Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Myeloid, Acute 14Leukemia 13Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, Mantle-Cell 4Burkitt Lymphoma 4Recurrence 3Myelodysplastic Syndromes 3Multiple Myeloma 3Waldenstrom Macroglobulinemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Hodgkin Disease 2Congenital Abnormalities 2Primary Myelofibrosis 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neutropenia 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Neutrophilic, Chronic 1

Interventions

blinatumomab 15Cyclophosphamide 15Cytarabine 14Azacitidine 11venetoclax 10fludarabine 10fludarabine phosphate 7Methotrexate 7Daunorubicin 7Rituximab 6Vincristine 5Mercaptopurine 5Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Dexamethasone 3Cladribine 3Busulfan 3Asparaginase 3thymoglobulin 2pembrolizumab 2pegaspargase 2nilotinib 2midostaurin 2daratumumab 2Vindesine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × etoposide phosphate × Other hematologic neoplasm × Clear all
NCT00198991 2022-08-18

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Goethe University

Phase 4 Completed
1,883 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡